Hospital
Dignity Community Care
Dignity Community Care was paid $19.72M by Medicaid between Jan 2018 and Nov 2024, across 207 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 15% of everything it billed.
33Billing provider infoDIGNITY COMMUNITY CARE
WOODLAND, CA 95695
WOODLAND, CA 95695
33aNPI1922116037assigned 08/28/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$19.72M
24GClaims512,394
24DCodes billed207
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in California
Rank by total paid#6 of 33
Median peer was paid$361K
This provider vs. median55×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 86,712 | $2.65M | |
| 2019 | 89,684 | $2.69M | |
| 2020 | 55,952 | $2.33M | |
| 2021 | 68,239 | $2.43M | |
| 2022 | 77,822 | $2.77M | |
| 2023 | 84,472 | $3.24M | |
| 2024incomplete | 49,513 | $3.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 15% | 34,445 | 29,941 | $2.92M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 40,055 | 34,452 | $2.86M |
| 0450 | Emergency room services | 9.6% | 7,898 | 7,021 | $1.89M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.2% | 4,502 | 4,335 | $1.02M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 5.1% | 6,275 | 5,663 | $1.00M |
| 99201 | 4.7% | 6,659 | 5,488 | $935K | |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 3,999 | 3,869 | $624K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 8,903 | 7,797 | $519K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 5,389 | 3,382 | $405K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 7,465 | 6,384 | $334K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.6% | 1,081 | 1,061 | $309K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 9,765 | 8,961 | $299K |
195 more codes
| J3490 | Unclassified drugs | 1.5% | 30,217 | $297K |
| 80053 | Comprehensive metabolic panel | 1.5% | 31,730 | $287K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.4% | 5,415 | $272K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 6,025 | $255K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 7,050 | $241K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 2,138 | $226K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,970 | $185K |
| 71250 | <1% | 1,455 | $183K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,387 | $167K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,257 | $161K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,861 | $152K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 723 | $149K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 822 | $146K |
| Z7502 | <1% | 3,771 | $141K | |
| 96367 | <1% | 1,640 | $140K | |
| 99284 | Emergency room visit (serious) | <1% | 773 | $135K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 1,852 | $127K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,658 | $123K |
| 99199 | Unlisted special service, procedure or report | <1% | 2,507 | $123K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,608 | $112K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,040 | $110K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,262 | $105K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 463 | $105K |
| 76830 | Ultrasound, transvaginal | <1% | 2,085 | $95K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 612 | $87K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,321 | $86K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,376 | $77K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 244 | $75K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,616 | $73K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,321 | $70K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,663 | $68K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,746 | $59K |
| 93971 | <1% | 669 | $56K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,128 | $56K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 192 | $50K |
| 84484 | <1% | 5,681 | $49K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,315 | $45K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,338 | $45K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,252 | $43K |
| 83880 | <1% | 2,041 | $42K | |
| 83690 | <1% | 9,280 | $42K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 254 | $38K |
| 0250 | <1% | 2,734 | $38K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 620 | $37K |
| 83605 | <1% | 4,952 | $37K | |
| 87040 | <1% | 3,513 | $37K | |
| 73221 | <1% | 157 | $37K | |
| 72141 | <1% | 295 | $37K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,321 | $35K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,497 | $33K |
| 73130 | <1% | 928 | $32K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,227 | $31K |
| 73630 | <1% | 874 | $30K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 913 | $30K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,798 | $29K |
| 99070 | <1% | 13,395 | $29K | |
| 76775 | <1% | 834 | $29K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 2,512 | $28K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,686 | $28K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 536 | $27K |
| Z9725 | <1% | 891 | $27K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 93 | $25K |
| 73560 | <1% | 886 | $25K | |
| 81001 | <1% | 9,483 | $25K | |
| 70486 | <1% | 149 | $25K | |
| 76536 | <1% | 618 | $24K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,008 | $23K |
| 84145 | <1% | 1,954 | $23K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 1,087 | $22K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,621 | $21K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,104 | $21K |
| 73610 | <1% | 595 | $20K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 242 | $19K |
| 95806 | <1% | 96 | $18K | |
| 82962 | <1% | 4,033 | $18K | |
| 87631 | <1% | 447 | $17K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 18 | $17K |
| 85730 | <1% | 4,226 | $17K | |
| J1815 | Injection, insulin, per 5 units | <1% | 298 | $17K |
| 85610 | <1% | 6,477 | $16K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,525 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,655 | $16K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,658 | $16K |
| 90715 | <1% | 625 | $16K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,440 | $14K |
| 93970 | <1% | 126 | $13K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 459 | $13K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 755 | $12K |
| 76870 | <1% | 195 | $12K | |
| 85379 | <1% | 1,834 | $12K | |
| 83735 | <1% | 2,404 | $12K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,338 | $11K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 479 | $11K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 477 | $11K |
| 76801 | <1% | 252 | $11K | |
| 85027 | <1% | 2,262 | $10K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 148 | $9K |
| 81025 | <1% | 3,156 | $9K | |
| 82550 | <1% | 1,557 | $9K | |
| 73110 | <1% | 185 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,078 | $9K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 54 | $9K |
| 87081 | <1% | 2,283 | $8K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,426 | $8K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 172 | $8K |
| 86141 | <1% | 1,352 | $8K | |
| 59025 | Fetal non-stress test | <1% | 639 | $8K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 140 | $7K |
| 87077 | <1% | 1,475 | $7K | |
| V2632 | Posterior chamber intraocular lens | <1% | 330 | $7K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,628 | $7K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 299 | $7K |
| 84703 | <1% | 1,546 | $7K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 610 | $6K |
| 87186 | <1% | 1,123 | $6K | |
| 73030 | <1% | 171 | $6K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,710 | $6K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 159 | $6K |
| 99285 | Emergency room visit (most serious) | <1% | 12 | $6K |
| 84100 | <1% | 526 | $5K | |
| 0270 | <1% | 297 | $5K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 483 | $5K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 916 | $5K |
| 82553 | <1% | 305 | $4K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 24 | $4K |
| 72100 | <1% | 104 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 85 | $3K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 315 | $3K |
| 88304 | <1% | 889 | $3K | |
| 99152 | <1% | 53 | $3K | |
| 87276 | <1% | 384 | $3K | |
| 88342 | <1% | 394 | $3K | |
| 96415 | <1% | 70 | $3K | |
| Z7610 | <1% | 1,052 | $3K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 24 | $3K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 27 | $3K |
| 93017 | <1% | 64 | $3K | |
| 94644 | <1% | 85 | $3K | |
| 86901 | <1% | 1,524 | $3K | |
| 87275 | <1% | 384 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 89 | $3K |
| 87070 | <1% | 354 | $2K | |
| 81003 | <1% | 1,379 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 431 | $2K |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 199 | $2K |
| 12001 | <1% | 59 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 126 | $2K |
| 85007 | <1% | 1,115 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 762 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 213 | $2K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 18 | $2K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 27 | $2K |
| 86885 | <1% | 579 | $1K | |
| 84702 | <1% | 234 | $1K | |
| 99406 | <1% | 101 | $1K | |
| 87205 | <1% | 412 | $1K | |
| 87075 | <1% | 145 | $1K | |
| 96417 | <1% | 16 | $1K | |
| 86900 | <1% | 787 | $1K | |
| 82803 | <1% | 56 | $959.88 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 273 | $940.87 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $596.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 55 | $504.92 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $499.24 |
| 76813 | <1% | 26 | $476.37 | |
| 87147 | <1% | 39 | $446.36 | |
| 36600 | <1% | 14 | $419.57 | |
| 97750 | <1% | 14 | $399.76 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 131 | $398.03 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 16 | $335.02 |
| 77080 | <1% | 38 | $323.96 | |
| A9150 | Non-prescription drugs | <1% | 2,858 | $288.16 |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 69 | $277.04 |
| 80061 | Lipid panel | <1% | 59 | $260.90 |
| 74019 | <1% | 14 | $252.69 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 26 | $240.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 167 | $239.21 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 41 | $229.82 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 53 | $166.40 |
| 87420 | <1% | 23 | $140.44 | |
| 82565 | <1% | 298 | $125.06 | |
| 84439 | <1% | 29 | $123.11 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 31 | $118.97 |
| 85651 | <1% | 51 | $90.59 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 43 | $70.98 |
| 84520 | <1% | 64 | $22.65 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 19 | $7.66 |
| 88311 | <1% | 13 | $4.74 | |
| G0151 | Services performed by a qualified physical therapist in the home health or hospice setting, each 15 minutes | 0% | 233 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 13 | $0.00 |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | 0% | 218 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 110 | $0.00 |
| 00140 | 0% | 17 | $0.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 143 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialD'ANGINA, JOSEPH (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY COMMUNITY CARE
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | Woodland, CA | $8.39M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.